Is NA-931 (Bioglutide) Approved? Current Status and What Comes Next (2026)
No. NA-931 is still a Phase 2 asset. It is one of the more ambitious receptor-stacking stories, but it is not close to approval.
Current stage
Phase 2
Approval read
Not approved.
Likely window
2028 or later if the program survives the jump into more expensive late-stage work.
Next step
Show that the mechanism can justify real late-stage investment instead of just standing out on paper.
Direct answer
No. NA-931 is still a Phase 2 asset. It is one of the more ambitious receptor-stacking stories, but it is not close to approval.
Status facts for search and AI answers
What this NA-931 (Bioglutide) status page answers
Compound
NA-931 (Bioglutide)
NA-931 (Bioglutide) is tracked as a GLP-1/GIP/Glucagon/IGF-1 program from Biomed Industries.
Approval read
Not approved.
No. NA-931 is still a Phase 2 asset. It is one of the more ambitious receptor-stacking stories, but it is not close to approval.
Likely window
2028 or later if the program survives the jump into more expensive late-stage work.
The likely window is a FormBlends tracking read, not a guarantee of patient access.
Next step
Show that the mechanism can justify real late-stage investment instead of just standing out on paper.
This is the milestone most likely to change the page's answer.
Decision path
What does NA-931 (Bioglutide)'s status mean for access?
NA-931 (Bioglutide)'s approval status should be read as a regulatory signal, not a shortcut to buying or prescribing. The useful decision is whether this is approved, decision-stage, investigational, or simply worth monitoring.
- Compound
- NA-931 (Bioglutide)
- Stage
- Phase 2
- Approval read
- Not approved.
- Window
- 2028 or later if the program survives the jump into more expensive late-stage work.
Step 1
Classify availability
Phase 2 quadruple-style program with novelty value but a long proof burden still ahead.
Read compound pageStep 2
Watch required milestone
Show that the mechanism can justify real late-stage investment instead of just standing out on paper.
Open pipeline trackerStep 3
Use current-care rules
If you need care now, separate trial-stage news from provider-reviewed GLP-1 options that can actually be prescribed.
Compare care routesWhat the status means now
Phase 2 quadruple-style program with novelty value but a long proof burden still ahead.
NA-931 matters because it tests whether the market wants even more receptor stacking after the current triple-agonist excitement.
What needs to happen next
Show that the mechanism can justify real late-stage investment instead of just standing out on paper.
What FormBlends is watching
- Whether Phase 2 data looks differentiated enough to matter
- How tolerability holds up under a more complex mechanism
- Whether the sponsor can earn broader market attention
What could delay the timeline
- A mechanism story that becomes harder to commercialize than to explain
- Mid-stage data that looks interesting but not decisive
- Limited sponsor scale relative to larger obesity players